The Survival Analysis Of Autologous Hematopoietic Stem Cell Transplantation In118Patients With Malignant Hematological Disease

Objective To evaluate the clinical efficacy of autologoushematopoietic stem cell transplantation (auto-HSCT) in the treatment ofmalignant hematological diseases.Methods The clinical data of118patients with hematological diseaseswho received auto-HSCT were collected. Of the118patients,23were acuteleukemia (AL),69were malignant lymphoma (ML) and26were multiplemyeloma (MM). The overall survival (OS), disease free survival (DFS),and the relapse rate were analyzed.Results Totally117patients engrafted successfully, except1patientdied because of infection. The average time was9.8d for neutrophilreconstruction (≥0.5×109/L), and12.3d for platelet reconstruction (≥20×109/L). Median survival time was47.6(1~80) months. The3-year OSand DFS were62.3%%and54.3%, the5-year OS and DFS were49.0%and42.8%, and the cumulative relapse frequencies was28.0%. In the ALgroup, the3-year and5-year OS were both46.2%,and the3-year and 5-year DFS were both37.3%;In ML group, the3-year OS and DFS were70.7%%and68.7%, the5-year OS and DFS were60.6%and57.6%;And inthe MM group, the3-year OS and DFS were55.1%%and37.2%, the5-year OS and DFS were33.1%and24.8%.Conclusion Auto-HSCT is effective for AL. Auto-HSCT canobviously prolong the survival time of ML and MM patients, and the MMshould get individualized treatment.